Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes

Dyslipidemia Clinical Trial

— DEMAND  

Official title:

Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01265836
• Other study ID #: NIS-CTH-DUM-2010/1
• Status: Withdrawn
• Phase: N/A
• First received: December 14, 2010
• Last updated: April 11, 2011
• Start date: March 2011
• Est. completion date: March 2013

Study information

• Verified date: April 2011
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: Thailand: Ministry of Public Health
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment (statin or combination) reaching the LDL-C goals according to the updated 2004 National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines.

Description:

MC MD

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 1064
• Est. completion date: March 2013
• Est. primary completion date: March 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Provision of subject informed consent, Female or male aged = 18 years

• Patients eligible for treatment of dyslipidemia with statins, according to the current guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention Receiving lipid-lowering drug treatment for at least 15 days.

Exclusion Criteria:

• Involvement in the planning and conduct of the study (applies to either AstraZeneca staff or staff at the study site).

• Previous enrolment or randomisation of treatment in the present study

• Participation in a clinical study during the last 90 days

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Dyslipidemia
• Dyslipidemias

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The number (#) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines.		1 year	No
Primary	The percent (%) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines.		1 year	No
Secondary	The number of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets		1 year	No
Secondary	The number of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1		1 year	No
Secondary	The number of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year		1 year	No
Secondary	The percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets		1 year	No
Secondary	The percent of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1		1 year	No
Secondary	The percent of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year		1 year	No